Small azurin derived peptide targets ephrin receptors for radiotherapy

International Journal of Peptide Research and Therapeutics

Volumn 17, Issue 3, 2011, Pages 247-257

  Micewicz, Ewa D ^a   Jung, Chun Ling ^a   Schaue, Dorthe ^a   Luong, Hai ^a,b   McBride, William H ^a   Ruchala, Piotr ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Artificial metastasis; Cancer radiotherapy; Ephrin receptors; Lewis lung carcinoma; Peptides; Targeted radiotherapeutics

Indexed keywords

AMIDE; AZURIN; AZV36 NICL PEPTIDE; EPHRIN RECEPTOR; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B4; NICOTINIC ACID; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CONJUGATION; CONTROLLED STUDY; DISULFIDE BOND; DRUG RECEPTOR BINDING; DRUG TARGETING; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LUNG METASTASIS; NONHUMAN; RAT;

EID: 83255191673     PISSN: 15733149     EISSN: 15733904     Source Type: Journal    
DOI: 10.1007/s10989-011-9265-9     Document Type: Article

References (41)

1. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS (2007) From combinatorial chemistry to cancer-targeting peptides. Mol Pharm 4:631-651 (Pubitemid 350004263)
2. Bonaparte MI, Dimitrov AS, Bossart KN et al (2005) Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci USA 102:10652-10657 (Pubitemid 41061609)
3. Castano J, Davalos V, Schwartz S Jr, Arango D (2008) EPH receptors in cancer. Histol Histopathol 23:1011-1023
4. Chaudhari A, Fialho AM, Ratner D et al (2006) Azurin, Plasmodium falciparum malaria and HIV/AIDS: inhibition of parasitic and viral growth by Azurin. Cell Cycle 5:1642-1648 (Pubitemid 44285250)
5. Chaudhari A, Mahfouz M, Fialho AM et al (2007) Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. Biochemistry 46:1799-1810
6. Cortina C, Palomo-Ponce S, Iglesias M et al (2007) EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet 39:1376-1383 (Pubitemid 350034995)
7. Cowan CA, Henkemeyer M (2001) The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature 413:174-179 (Pubitemid 32867879)
8. Crane CH, Das P (2007) Potential benefits of integration of therapies with chemoradiation in rectal cancer. Gastrointest Cancer Res 1:S73-S80
9. Crane BR, Di Bilio AJ, Winkler JR, Gray HB (2001) Electron tunneling in single crystals of Pseudomonas aeruginosa azurins. J Am Chem Soc 123:11623-11631 (Pubitemid 33123183)
10. Cui ZY, Ahn JS, Lee JY et al (2006) Mouse orthotopic lung cancer model induced by PC14PE6. Cancer Res Treat 38:234-239
11. Fazio MA, Oliveira VX Jr, Bulet P, Miranda MT, Daffre S, Miranda A (2006) Structure-activity relationship studies of gomesin: importance of the disulfide bridges for conformation, bioactivities, and serum stability. Biopolymers 84:205-218
12. Fields GB, Noble RL (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35:161-214 (Pubitemid 20126875)
13. Fox BP, Kandpal RP (2004) Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 318:882-892 (Pubitemid 38625856)
14. Gale NW, Baluk P, Pan L et al (2001) Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 230:151-160 (Pubitemid 32171414)
15. Gobin AM, Moon JJ, West JL (2008) EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells. Int J Nanomed 3:351-358
16. Grunt TW, Lametschwandtner A, Karrer K (1986a) The characteristic structural features of the blood vessels of the Lewis lung carcinoma (a light microscopic and scanning electron microscopic study). Scan Electron Microsc 2:575-589
17. Grunt TW, Lametschwandtner A, Karrer K, Staindl O (1986b) The angioarchitecture of the Lewis lung carcinoma in laboratory mice (a light microscopic and scanning electron microscopic study). Scan Electron Microsc 2:557-573
18. Heroult M, Schaffner F, Augustin HG (2006) Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 312:642-650 (Pubitemid 43290340)
19. Hong SY, Oh JE, Lee KH (1999) Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol 58:1775-1780 (Pubitemid 29505418)
20. Jackson D, Gooya J, Mao S et al (2008) A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 68:9367-9374
21. Kiewlich D, Zhang J, Gross C et al (2006) Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia 8:18-30
22. Kinch MS, Moore MB, Harpole DH Jr (2003) Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9:613-618 (Pubitemid 36182592)
23. Knip M, Douek IF, Moore WP et al (2000) Safety of high-dose nicotinamide: a review. Diabetologia 43:1337-1345
24. Koolpe M, Dail M, Pasquale EB (2002) An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 277:46974-46979 (Pubitemid 36159202)
25. Koolpe M, Burgess R, Dail M, Pasquale EB (2005) EphB receptorbinding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem 280: 17301-17311 (Pubitemid 41389199)
26. Liu CC, Young JD (1988) A semi-automated microassay for complement activity. J. Immunol Methods 114:33-39 (Pubitemid 18260005)
27. Murai KK, Pasquale EB (2003) 'Eph'ective signaling: forward, reverse and crosstalk. J Cell Sci 116:2823-2832 (Pubitemid 36926971)
28. Murai KK, Nguyen LN, Koolpe M, McLennan R, Krull CE, Pasquale EB (2003) Targeting the EphA4 receptor in the nervous system with biologically active peptides. Mol Cell Neurosci 24: 1000-1011 (Pubitemid 38091512)
29. Nitsche M, Christiansen H, Hermann RM et al (2008) The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro. Int J Radiat Biol 84:643-657
30. Noberini R, Koolpe M, Peddibhotla S et al (2008) Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 283:29461-29472
31. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB (2004) Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA 101: 5583-5588 (Pubitemid 38481199)
32. Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8:98-101
33. Pasquale EB (2004) Eph-ephrin promiscuity is now crystal clear. Nat Neurosci 7:417-418 (Pubitemid 38544565)
34. Pasquale EB (2005) Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6:462-475 (Pubitemid 40780558)
35. Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38-52 (Pubitemid 351442996)
36. Ruddock MW, Hirst DG (2007) Metabolites of the radiosensitizer nicotinamide are unlikely to contribute to the degree of emesis observed with the parent drug. Oncol Res 16:569-574 (Pubitemid 351344779)
37. Scarberry KE, Dickerson EB, McDonald JF, Zhang ZJ (2008) Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J Am Chem Soc 130:10258-10262
38. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG (2009) Genetic analysis of radiation-induced changes in human gene expression. Nature 459:587-591
39. Song J (2003) Tyrosine phosphorylation of the well packed ephrinB cytoplasmic beta-hairpin for reverse signaling. Structural consequences and binding properties. J Biol Chem 278:24714-24720 (Pubitemid 37548628)
40. Vaught D, Brantley-Sieders DM, Chen J (2008) Eph receptors in breast cancer: roles in tumor promotion and tumor suppression. Breast Cancer Res 10:217
41. Wykosky J, Gibo DM, Debinski W (2007) A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther 6:3208-3218